Discovery of New Antibodies Against HIV A Case Study of a Global Partnership Prof. Omu Anzala Program Director Kenya AIDS Vaccine Initiative (KAVI) Department.

Slides:



Advertisements
Similar presentations
IAVIs Brooklyn Design Laboratory/Historic Tax Credit Transaction By Mike Goldrich Executive Vice President & COO June 24, 2009.
Advertisements

Pediatric Diagnosis of HIV-1 Infection Using Dried Blood Spots Chin-Yih Ou, PhD NCHSTP/DHAP Centers for Disease Control and Prevention.
Pox-Protein Public-Private Partnership (P5)
A)A) B)B) C)C) D)D) E)E) Bergin P 1, Langat R 2, Omosa-Manyonyi G 2, Farah B 2, Bizimana J 3, Umvirigihozo G 3, Nyombayire J 3, Ouattara G 2, Ingabire.
Leukemia is characterized by abnormal white blood cells.
An Introduction to HIV Incidence Surveillance (HIS) in California California Department of Public Health Office of AIDS.
Immune Response Humoral Immune Response – Activation of B-Cells to produce antibodies Cell-mediated Immune Response – Activation of cytotoxic T-Cells.
A. D. Smith, 1 A. Muhaari 2 E. M. van der Elst 2 D. Kowuor, 2 A.Davies, 2 C Agwanda, 1 M. Price, 3 F. Priddy, 3 H. S. Okuku, 2 S.M. Graham, 4 E. J. Sanders.
Prof. Fatma Amer Medical Microbiology and Immunology, ZAGAZIG FACULTY OF Medicine, Egypt President of ISC/HWG President of ArAPUA In the Era of Direct.
CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.
Informatics Support for Vaccine Projects Using and extending the UCSC bioinformatics infrastructure.
National Vaccine Advisory Committee November 29, 2005 Update on NIH H5N1 Vaccine Trials Linda C. Lambert Chief, Respiratory Diseases Branch Division of.
Enhancing HIV/AIDS Surveillance in California California Department of Public Health Office of AIDS Guide for Health Care Providers.
Vaccinations, white blood cells, antibodies By Alex Hayes.
Preventing HIV/AIDS There is no way to tell just by looking whether a person is infected with HIV. Because people are unaware that they are HIV-positive,
Volunteers’ Perceptions and Experiences of Clinical Research Participation in Kenya: Case study of KAVI Emily Nyariki PhD Student KAVI, Department of Medical.
The Immune System Pathogen : Viruses, bacteria, and other microorganisms that cause disease are called pathogens. Infection: Invasion of the tissues of.
Immunoassays Group 1: Kateryna Dyakiv, Emina Hodzic, Chris Mecinski, Nicholas Anaya, and Andrew Strmic.
HIV Vaccine Research & Development
HIV Vaccine Clinical Trials: In Theory and on the Ground Prof. Omu Anzala Program Director Kenya AIDS Vaccine Initiative (KAVI) Department of Medical Microbiology.
HIV/AIDS is preventable and treatable, but is incurable.
Partnerships in Promoting Innovation and Managing Risk Scientific and Financial Innovation in AIDS Vaccines International AIDS Vaccine Initiative Labeeb.
Immune correlates of unusual control of viral replication after cessation of HAART Ellen Van Gulck 1, Leo Heyndrickx 1, Céline Merlin 1, Sandra Coppens.
18.3 Viral Diseases KEY CONCEPT Some viral diseases can be prevented with vaccines.
Introduction to Basic Science Emily L. Lowe, Ph.D. Microbiology, Immunology and Molecular Genetics UCLA.
ART Program of the HIV Vaccine Trials Network Margaret Wecker, PhD Associate Director, Scientific Operations and Business Development.
Emily Salmon Norman Purvis, PhD, Esoterix Development, Simulation and Optimization of Oncology Laboratory Sample Processing Automation.
DoHDST. South African AIDS Vaccine Initiative (SAAVI)  Established in late1999 by the South African government.  Based at the Medical Research Council.
Detection of Immune Responses in Mucosal T-cells in Kenya Jackton Indangasi 2, Hannah Cheeseman 1, Onyango J. I. Obila 2, Simon Ogola 2, Robert Langat.
EFFECTS OF SEXUAL ACTIVITY ON IMMUNE ACTIVATION AMONG HIV- EXPOSED SERONEGATIVE FEMALES AT PUMWANI CLINIC, NAIROBI Abel Onyango, PhD student Kenya AIDS.
The Berlin Patient and CCR5. Tim Brown: the only man to have been cured of HIV  Brown was diagnosed with HIV in 1995  11 years on antiretroviral therapy.
HIV diagnosis (general) ImmunoassaysNAT (PCR)
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Lab of Immunoregulation Berkower Lab Weiss Lab -- Angelo Spadaccini -- Russell Vassell -- Yisheng Ni -- Yong He -- Yisheng Ni -- Yong He –Hong Chen --
After a virus becomes active and replicates in a host cell, it destroys the host cell. Copies of the virus are then released into the host organism, where.
Dr. Jeffrey Dorfman Cellular Immunology ICGEB Cape Town Autoreactivity of anti-HIV-1 neutralizing antibodies does not prevent broad antibody responses.
AIDS Vaccines: the basics CindraFeuer AVAC: Global Advocacy for HIV Prevention 20 April 2010 The HIV Research Catalyst Forum Baltimore, Maryland April.
The AIDS Vaccine Policy Agenda Holly J. Wong Vice President, Public Policy International AIDS Vaccine Initiative (IAVI) Vienna, Austria International AIDS.
ANIMAL MODELS FOR HIV VACCINES Girish N. Vyas, Ph.D. UCSF School of Medicine, San Francisco (UCSF) A quote from the keynote Address at the January, 2008.
ELISA Enzyme-Linked Immunosorbent Assay. What is an assay? An analysis done on a substance to determine the presence of a target substance and sometimes,
HIV/AIDS is preventable and treatable, but is incurable.
Research on killer HIV antibodies provides promising new ideas for vaccine design New discoveries about the immune defenses of rare HIV patients who produce.
Blood Tests (“Labs”) 1. “Labs” Regular blood tests are a crucial part of HIV health care. They are often referred to as “bloods” or “labs” Several important.
Human clinical trial of DNA-MVA HIV vaccine candidate begins A Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector.
Thorny Issues in HIV Vaccine Trials Saul Walker Policy Advisor IAVI.
25 Years of HIV Vaccine Research: What have we accomplished? José Esparza MD, PhD Senior Advisor on HIV Vaccines Global Health Program The Search for an.
Immune system the system in the body that works to ward off infection and disease.
HUMAN IMMUNODEFICIENCY VIRUS AND ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
Specialties and your career. Starting work in a lab When you apply for your first job in a laboratory it will be in a specific discipline: haematology.
CATEGORY: VACCINES & THERAPEUTICS HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK HIV-1 Vaccines © The copyright for this work resides.
$1 Million $500,000 $100,000 $50,000 $25,000 $10,000 $5,000 $1,000.
Lesson Overview Lesson Overview Immune System Disorders Lesson Overview 35.4 Immune System Disorders.
HIV Infection Chapter 30 Lesson One pg. 658 Global burden of HIV Over 25 million have died from AIDS leading cause of death in developing countries (WHO.
Overview and facts of AIDS Presented By Dr. Liza Watts Lisa Watts is a recognized social activist. She runs a NGO that spreads AIDS.
Adaptive trial designs in HIV vaccine clinical trials Morenike Ukpong Obafemi Awolowo University Ile-Ife, Nigeria.
Promoting innovation through research networks: IAVI and our global partners Holly Wong International AIDS Vaccine Initiative (IAVI) August 3, 2008.
Unit Question: What is life and how does it maintain balance? Notes #8: The Immune System and Homeostasis Aim: What does your immune system do? Name:________________.
HVTN 702: A pivotal phase 2b/3 multi-site, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of ALVAC-HIV.
New Priorities for IAVI Dr. Seth Berkley President & CEO, International AIDS Vaccine Initiative 4 August 2008 XVII International AIDS Conference Mexico.
department < clinical chemistry, microbiology and immunology >
Non-ARV Based Interventions to Combat HIV/AIDS: New Insights and Initiatives Yves Lévy Inserm, VRI.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
HIV targets the immune system.
? Neutralizing Antibodies: Research pathways in 2013 and beyond
Higher Human Biology Unit 3 – Neurobiology and Immunology
B cell T cell.
Third Line of Defense Immune Response (Specific Defense)
KEY CONCEPT Some viral diseases can be prevented with vaccines.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Presentation transcript:

Discovery of New Antibodies Against HIV A Case Study of a Global Partnership Prof. Omu Anzala Program Director Kenya AIDS Vaccine Initiative (KAVI) Department of Medical Microbiology University Of Nairobi Kenya

2 HIV Life Cycle & Vaccine Design Cell Mediated Immunity Neutralizing Antibodies

3 This is the neutralizing antibody challenge  Most licensed vaccines work by inducing the body to produce antibodies that attack the infecting virus, neutralizing most of it and enabling the immune system to clear remaining virus before the onset of disease  In the blood of certain HIV-infected individuals, scientists have identified special antibodies that are broadly neutralizing—they neutralize many of the types of HIV in circulation worldwide  An AIDS vaccine will almost certainly need to elicit a sufficient amount of these broadly neutralizing antibodies The Neutralizing Antibody Challenge

4 Solve the Neutralizing Antibody Problem Goal: Advance to clinical trials candidate(s) which elicit HIV-specific broadly neutralizing antibodies Broadly neutralizing antibodies against HIV exist Sera from HIV+ (4) broadly neutralizing monoclonal antibodies (bnMAbs) Vaccine design targeting binding sites for the 4 bnMAbs has thus far failed New, more potent, broadly neutralizing antibodies which target novel sites on HIV Env are needed to facilitate vaccine design

5 Protocol G - Overview Purpose: To generate novel potent and broad neutralizing monoclonal antibodies (bnMAbs) from HIV infected subjects who have broadly neutralizing serum activity Methods:Screen HIV infected individuals for broadly neutralizing serum activity Key issue: Validated screening assay Select subjects with broad and potent neutralization activity Key Issue: Cohorts in the developing world Derive bnMAbs from their PBMCs Key Issue: Multiple technologies to increase the chances of success Study population: N=2000 Adults infected with HIV at least 3 years Without advanced disease Not on ART Non-B clades prioritized

6 1. Nearly 2,000 blood samples collected from HIV-positive individuals around the world IAVI Human Immunology Laboratory, London Number of donor samples from each site Monogram Biosciences 2. Samples sent to Monogram Biosciences for neutralization screening The Antibody Project: Protocol G

7 3. Screening results scored using new IAVI algorithm to identify donors of interest About 1% are “elite neutralizers” Blood samples collected About 10% are donors of interest The Antibody Project: Identifying Prospects

8 4. After data review, new samples requested from donors of interest IAVI NAC at Scripps 5. Samples sent to IAVI Human Immunology Laboratory IAVI Human Immunology Laboratory, London The Antibody Project: Closing In

9 IAVI Human Immunology Laboratory 6. Samples sent to four partner labs for antibody rescue—each using a different technology Theraclone Rockefeller University IAVI NAC at Scripps HuMabs Monogram* *Monogram received new samples to verify neutralization screenings The Antibody Project: Partners in the Hunt

10 Chennai Pune Kilifi Rustenburg Cape Town Lusaka Copperbelt Kigali Masaka Entebbe Nairobi 10. Ultimately, the process comes full circle with clinical testing of vaccine candidates IAVI-supported network of clinical research centers The Antibody Project: The Return

11 Progress: Case Study on Neutralizing Antibodies

12 Taking the lead Paradigm shift. Trans-disciplinary To achieve this international global network

13

14 Questions?

15